ArticleInfection and drug resistance2022
The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole in
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- The β-lactam adjuvant guanosine potentiates anti-folate antibiotics and pyrimidine synthesis inhibitors by depleting thymidine in methicillin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Article
- The β-lactam adjuvant guanosine potentiates anti-folate antibiotics and pyrimidine synthesis inhibitors by depleting thymidine in methicillin-resistantbioRxiv : the preprint server for biology · 2026Article
- Molecular landscape of methicillin-resistantJAC-antimicrobial resistance · 2025Article
- Evaluation of Adverse Events Associated with the Sulfamethoxazole/Trimethoprim Combination Drug.Journal of clinical medicine · 2025Article
- Antimicrobial resistance trends of methicillin-resistantJAC-antimicrobial resistance · 2025Article
- Genome-wide analysis of fitness determinants of Staphylococcus aureus during growth in milk.PLoS pathogens · 2025Article
- Ceftazidime-Induced Overexpression of MexJK-OprM Confers Resistance to Ceftolozane/Tazobactam in an Isolate ofInfection and drug resistance · 2025Article
- Optimizing Antimicrobial Use in Japan: Strategies for Dosage, Combination Therapy, De-Escalation, Oral Switching, Duration, and Guideline Adherence.Clinical pharmacology : advances and applications · 2025Review
- Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-SusceptibleLife (Basel, Switzerland) · 2023Article
- Molecular Basis of Non-β-Lactam Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Due to the spread of community-acquired methicillin-resistant Methods: A total of 40 Results: The SXT-resistant strain began to emerge on the eighth day and accounted for 45% (18/40 clinical isolates) after 14 days. Moreover, one half of these resistant strains showed F98Y mutation in DfrB to retain SXT-resistance without selective pressure. Conclusion: The emergent risk was SXT exposure of 14 days or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.